NCT00320827View on ClinicalTrials.gov

Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component)

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

Not specified

Conditions
MalignanciesLymphoma
Interventions
DRUG

CS-1008 (humanized anti-DR5 antibody)

Trial Locations (1)

35294-3300

University of Alabama at Birmingham, Birmingham

Sponsors

Lead Sponsor

Daiichi Sankyo
All Listed Sponsors
lead

Daiichi Sankyo

INDUSTRY

NCT00320827 - Study of CS-1008 in Patients With Advanced Solid Malignancies and Lymphomas (Without Leukemic Component) | Biotech Hunter | Biotech Hunter